STAAR Surgical (NASDAQ:STAA) Receives Consensus Recommendation of “Hold” from Analysts

STAAR Surgical (NASDAQ:STAA) has been given a consensus rating of “Hold” by the ten analysts that are currently covering the stock, Marketbeat Ratings reports. Six research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $46.38.

A number of equities analysts have issued reports on STAA shares. Piper Sandler lowered their target price on STAAR Surgical from $40.00 to $33.00 and set a “neutral” rating for the company in a report on Tuesday, February 27th. Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a report on Thursday, April 4th. William Blair raised shares of STAAR Surgical from a “market perform” rating to an “outperform” rating in a report on Thursday, April 4th. Stifel Nicolaus restated a “buy” rating and issued a $50.00 price target on shares of STAAR Surgical in a research report on Monday, April 1st. Finally, Mizuho lifted their price target on shares of STAAR Surgical from $45.00 to $53.00 and gave the stock a “buy” rating in a report on Thursday, April 11th.

Insider Activity

In other news, Director Aimee S. Weisner bought 1,750 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The shares were bought at an average cost of $38.11 per share, for a total transaction of $66,692.50. Following the acquisition, the director now directly owns 10,864 shares in the company, valued at $414,027.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.10% of the company’s stock.

Institutional Trading of STAAR Surgical

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Clear Street Markets LLC purchased a new position in shares of STAAR Surgical during the third quarter valued at approximately $29,000. GAMMA Investing LLC grew its stake in shares of STAAR Surgical by 313.9% in the 1st quarter. GAMMA Investing LLC now owns 1,308 shares of the medical instruments supplier’s stock worth $50,000 after acquiring an additional 992 shares in the last quarter. Cape Investment Advisory Inc. purchased a new stake in shares of STAAR Surgical in the fourth quarter valued at about $42,000. Nisa Investment Advisors LLC raised its holdings in shares of STAAR Surgical by 415.8% in the third quarter. Nisa Investment Advisors LLC now owns 2,445 shares of the medical instruments supplier’s stock valued at $98,000 after purchasing an additional 1,971 shares during the last quarter. Finally, Covestor Ltd lifted its position in shares of STAAR Surgical by 82,466.7% during the third quarter. Covestor Ltd now owns 2,477 shares of the medical instruments supplier’s stock valued at $100,000 after purchasing an additional 2,474 shares in the last quarter. 96.70% of the stock is owned by institutional investors.

STAAR Surgical Trading Down 0.1 %

Shares of STAAR Surgical stock opened at $45.51 on Wednesday. The firm’s 50 day moving average is $41.38 and its 200 day moving average is $35.78. The firm has a market capitalization of $2.24 billion, a PE ratio of 105.84 and a beta of 0.80. STAAR Surgical has a 1 year low of $26.66 and a 1 year high of $69.00.

STAAR Surgical (NASDAQ:STAA) last posted its earnings results on Monday, February 26th. The medical instruments supplier reported $0.16 earnings per share for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.01). The company had revenue of $76.27 million for the quarter, compared to the consensus estimate of $75.94 million. STAAR Surgical had a return on equity of 8.73% and a net margin of 6.62%. The business’s quarterly revenue was up 19.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.04 EPS. As a group, research analysts anticipate that STAAR Surgical will post 0.03 earnings per share for the current year.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.